Paragon Bioservices Revenue and Competitors

Claim your profile

Location

$20M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Paragon Bioservices's estimated annual revenue is currently $24.3M per year.(i)
  • Paragon Bioservices received $5.0M in venture funding in August 2018.
  • Paragon Bioservices's estimated revenue per employee is $155,000
  • Paragon Bioservices's total funding is $20M.

Employee Data

  • Paragon Bioservices has 157 Employees.(i)
  • Paragon Bioservices grew their employee count by -21% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$6.2M40-2%$17.5MN/A
#2
$15.7M101-7%$10.5MN/A
#3
$17.8M115-3%$69.4MN/A
#4
$2M1344%$40MN/A
#5
$5.6M36N/AN/AN/A
#6
$1.4M9-31%N/AN/A
#7
$2.8M18N/A$34.7MN/A
#8
$2.6M17N/AN/AN/A
#9
$1.7M1122%N/AN/A
#10
$2M1344%$10.6MN/A

Paragon Bioservices is an industry-leading, private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of cutting-edge biopharmaceuticals. Paragon's aim is to build strong client partnerships with the world's best biotech and pharma companies, focusing on transformative technologies, including gene therapies (AAV), next-generation vaccines, oncology immunotherapies (oncolytic viruses and CAR-T cell therapies), therapeutic protein, and other complex biologics.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$20M

Total Funding

157

Number of Employees

$24.3M

Revenue (est)

-21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Paragon Bioservices News

2014-10-28 - Paragon Bioservices Raises $13M in Series A Financing

Paragon Bioservices, Inc., a Baltimore, MD-based contract research and manufacturing organization that aims to accelerate the development and manufacturing of biopharmaceuticals and vaccines, raised $13m in Series A financing. The round was led by NewSpring Capital and Camden Partners. In conju ...

2014-11-04 - Paragon Bioservices raises $13M to expand CRO/CMO work in vaccines, biologics

The company also just brought on a new COO, Pete Buzy, to its leadership team. The guy was formerly CFO of Martek Biosciences for 13 years, and helped orchestrate its $1.1 billion sale to Royal DSM. “Market factors, including the consolidation of the pharmaceutical industry and the growth of vi ...

2018-01-25 - Paragon Bioservices Bolsters Leadership Ranks with Executive Appointments

Paragon Bioservices, the leading private equity-backed biologics contract development and manufacturing organization (CDMO) with proven expertise in gene therapy and next-generation vaccines, announces today the promotion of key personnel and the addition of two industry veterans to its leadersh ...

09/07/2019 - Viral vector and plasmid market set for rapid growth

Just this year, Catalent bought out California-based Paragon Bioservices? and Thermo Fisher Scientific acquired Brammer Bio?, located in ...

09/08/2019 - Catalent's legacy business outshined by acquisitions

By April of 2019, Catalent had agreed to a $1.2 billion acquisition of gene therapy developer Paragon Bioservices. And most recently, the ...

04/26/2019 - Why Paragon Bioservices' $1.2B acquisition deal matters to ...

Why Paragon Bioservices' $1.2B acquisition deal matters to Baltimore ... it had agreed to acquire Paragon Bioservices in a $1.2 billion deal.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$24.6M15841%$49.6M
#2
$46.9M15833%N/A
#3
$31.5M159N/AN/A
#4
$21.3M16111%N/A
#5
$48.1M1624%N/A

Paragon Bioservices Funding

DateAmountRoundLead InvestorsReference
2014-10-29$13.0MUndisclosedNewSpring CapitalArticle
2015-08-21$2.0MUndisclosedArticle
2018-08-14$5.0MUndisclosedArticle